This clinician education session with Anjali Malik, MD, reviews the current state of mammography for breast cancer screening in 2026. The discussion addresses evolving screening guidelines, advances in imaging technology, breast density considerations, and ongoing areas of clinical debate to support evidence-based screening and patient counseling.

This clinician education session with Angela Fitch, MD, FACP, FOMA, provides an up-to-date review of GLP-1–based therapies, including injectable and oral options and agents in the development pipeline. The discussion covers mechanisms of action, efficacy and safety data, clinical indications, and practical considerations for prescribing and patient counseling.

Jennifer Lanoff, WHNP-BC, MSCP, presents a clinician framework for identifying the Pelvic Pain Pentad — endometriosis, MCAS, POTS, hEDS, and pelvic venous disease — and the overlapping presentations that make this constellation so frequently missed.

Dr. Suzanne Gilberg-Lenz — board-certified OB/GYN, integrative medicine specialist, and author of Menopause Bootcamp — delivers an evidence-based review of botanical therapies in midlife, with practical guidance for clinical practice.

Dr. Lisa Chacko, founder of Curate Medical and architect of the "menopause-informed care" framework, examines the forces reshaping menopause care delivery — and what clinicians need to know to stay ahead of them.

HERmedicine's Monday Night Discussion Group is back with another expert-led session — details to follow. Check back soon for speaker and topic announcements.

The gut microbiome plays a surprising and significant role in women's hormonal health — and its connection to menopause is an area of rapidly growing research. In this HERtalks event, pharmacist and microbiome specialist Dragana Skokovic-Sunjic breaks down what the current evidence tells us and what it means for women navigating the menopausal transition.

In honor of Memorial Day, HERmedicine's Monday Night Discussion will not meet on May 26th. We'll be back the following week with more women's health education. Wishing our community a meaningful and restful holiday.

This clinician education session with Susan Brian, MD examines metabolic disease in midlife, with a focus on diabetes, insulin resistance, and cardiometabolic risk. The discussion reviews key metabolic changes, risk assessment, and evidence-based management strategies to support patient-centered care during midlife.

NK3 receptor antagonists represent a significant addition to non-hormonal menopause management — but applying the evidence to clinical practice requires a clear-eyed look at the data. Dr. Jill Liss, Associate Clinical Professor at the University of Colorado and MSCP-certified menopause specialist, breaks down the mechanism, the trial outcomes, and the patient populations most likely to benefit in this focused MNDG clinical update.

Female sexual dysfunction affects a significant proportion of midlife women — yet it remains consistently underaddressed in clinical settings. This MNDG session pairs two of the field's most recognized experts, Drs. Sheryl Kingsberg and Sharon Parish, for a focused update on where the evidence stands and what it means for practice: from testosterone and hormone therapy to pharmacologic treatments for HSDD and GSM.

A one-day, in-person CME covering menopause management, MHT prescribing, GLP-1 therapies, cardiometabolic risk, and breast cancer screening — led by nationally recognized women's health faculty. 7 AMA PRA Category 1 Credits™. June 19, 2026, Cincinnati, OH.

What if the foundational assumptions driving three decades of Alzheimer's research and drug development are wrong? Dr. Alberto Espay, one of neurology's most provocative and rigorous scientific voices, presents a data-driven challenge to the amyloid hypothesis and a new framework for understanding Alzheimer's disease genetics, pathogenesis, and clinical implications. A session that will change how you read the literature.

Multigene panel testing has reshaped how clinicians identify and manage hereditary breast cancer risk — but the evidence base for moderate-risk genes is still evolving, and translating test results into clinical action remains complex. Dr. Allison Kurian, Director of Stanford's Women's Clinical Cancer Genetics Program and a leading voice in cancer genetics guideline development, delivers a focused clinical update on where the science stands and what it means for your patients.

Ductal carcinoma in situ is evolving rapidly — and so is the evidence guiding its management. In this CME session, Dr. Laura Esserman provides a current, evidence-based review of DCIS diagnosis, risk stratification, and treatment, including emerging data on active surveillance and the growing movement away from overtreatment.

Abnormal uterine bleeding in perimenopausal and menopausal women is a common but clinically complex presentation. In this session, Dr. Steven Goldstein offers a systematic, evidence-based framework for evaluation — covering imaging, endometrial sampling, and the clinical decision points that guide management.

Perimenopause begins earlier than most clinicians and patients realize — and the evidence is reshaping how we define and respond to it. In this session, Dr. Marcie Richardson reviews the science of perimenopause onset, including the Late Reproductive Stage, and offers practical strategies for identifying and supporting women earlier in the transition.

GLP-1 receptor agonists have transformed Type 2 diabetes care — but they are not the only tool available. In this session, Dr. Jyothi Joseph-Hayes provides a practical, evidence-based review of the full range of diabetes medications beyond GLP-1s, helping clinicians make more individualized treatment decisions for their patients.

The WISDOM Study has enrolled more than 80,000 women to compare annual mammography with personalized, risk-based breast cancer screening — and the Phase 1 results are practice-changing. In this session, Allison Fiscalini presents the latest findings and what they mean for clinical screening guidelines and shared decision-making.

Most clinicians who see adolescent patients haven't had formal training in pediatric and adolescent gynecology — and the gap shows up in delayed diagnoses, missed referrals, and patients who don't feel heard. Dr. Leslie Appiah, a fellowship-trained specialist and nationally recognized leader in reproductive health equity, delivers a focused, practical session designed to close that gap for non-specialist providers.

For many women, perimenopause marks a significant worsening of migraine — and clinicians need a clear framework for managing it. Dr. Katherine Hamilton, a board-certified headache specialist at MedStar Georgetown's Headache Center, brings her expertise in hormonal migraine and women's headache care to this MNDG session, addressing the evidence for acute and preventive treatment approaches and the practical considerations around hormone therapy use in perimenopausal migraine patients.

Not every menopause patient fits the guidelines — and those are often the most important patients to get right. Dr. Risa Kagan, one of the country's leading menopause specialists, uses a case-based format to work through complex clinical scenarios and sharpen decision-making beyond the standard of care.

Orgasmic dysfunction is common, clinically significant, and consistently undertreated — in large part because providers lack a clear framework for addressing it. Dr. Lauren Streicher, founder of Northwestern's Center for Menopause and Sexual Health and one of the country's most respected voices in female sexual medicine, delivers an evidence-based review of orgasmic function across the menopausal transition and the pharmacologic and non-pharmacologic interventions that can make a meaningful clinical difference.

Dr. Connie Lehman brings the science of AI and radiomics in breast imaging to MNDG — exploring how these tools are reshaping risk stratification, screening precision, and clinical decision-making in breast health.

For many clinicians, the intersection of MHT and elevated breast cancer risk is where the conversation stalls. Dr. Sabrina Sahni — one of a small number of physicians with dual fellowship training in specialized women's health and medical breast — delivers a structured clinical framework for risk stratification and MHT counseling across the spectrum of breast risk, from benign breast disease and dense breasts to BRCA carriers and cancer survivors.

Should estradiol levels guide hormone therapy management — and if so, when? Drs. Sarah Glynne and James Simon bring complementary clinical perspectives from both sides of the Atlantic to this MNDG session, presenting a structured, evidence-informed case for estradiol monitoring as a tool to optimize MHT dosing, address persistent symptoms, and navigate safety considerations in complex patients.

The new nutrition and physical activity guidelines arrive in a clinical environment already shaped — and frequently distorted — by social media. Drs. Karl and Spencer Nadolsky, whose careers span endocrinology, obesity medicine, and evidence-based health communication, deliver a clinician-focused review of what has changed in the guidelines, what the evidence supports, and how to apply that knowledge in a practice landscape where patients often walk in with strong, algorithm-fed opinions.

Women with hereditary cancer risk present complex, longitudinal clinical challenges that extend well beyond the genetics consultation. Dr. Michelle Jacobson — lead author of national guidelines on hereditary cancer and menopause management and director of one of Canada's leading familial ovarian cancer programs — delivers a focused clinical review of what evidence-based risk management looks like in practice: from BRCA counseling and risk-reducing surgery to surveillance protocols and the nuanced intersection of menopause care and oncologic safety.

Thyroid disorders disproportionately affect women — and the autoimmune forms present distinct clinical challenges across the reproductive lifespan. Dr. Abid Yaqub, a board-certified endocrinologist and thyroid specialist at the University of Cincinnati, provides a structured clinical update on postpartum thyroiditis, Hashimoto's, and Graves' disease: their overlapping and distinguishing features, diagnostic workup, and the management decisions that matter most for women's health providers.